\n
\r\n<\/a>\r\n<\/p>\n<\/div><\/section><\/div>
\r\n\r\n
<\/a>\r\n<\/div><\/p>\n<\/div><\/section>
\nCN Bio appoints Neil Rumbelow as director of product development<\/h1>E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>

\n
CN Bio appoints Neil Rumbelow as director of product development<\/h1>E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\nCN Bio, a leading UK Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems, has appointed Neil Rumbelow as director of product development.<\/h3>\n
\nWithin the past year, CN Bio has made a series of leadership appointments to support delivery of its ambitious growth strategy across key global markets, in response to rising demand for the company\u2019s OOC solutions by pharma and biotech companies. Rumbelow joins the team to drive the scale-up of its
\nR&D activities, where he will work closely with recently-appointed chief scientific officer, Dr Tomasz Kostrzewski, to expand the company\u2019s PhysioMimix OOC range of MPS and incorporate the latest technological advances in the field to further extend their applications within preclinical research.<\/p>\n<\/div><\/section>
\n
CN Bio, a leading UK Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems, has appointed Neil Rumbelow as director of product development.<\/h3>\n
\nWithin the past year, CN Bio has made a series of leadership appointments to support delivery of its ambitious growth strategy across key global markets, in response to rising demand for the company\u2019s OOC solutions by pharma and biotech companies. Rumbelow joins the team to drive the scale-up of its
\nR&D activities, where he will work closely with recently-appointed chief scientific officer, Dr Tomasz Kostrzewski, to expand the company\u2019s PhysioMimix OOC range of MPS and incorporate the latest technological advances in the field to further extend their applications within preclinical research.<\/p>\n<\/div><\/section>
\n
\nWithin the past year, CN Bio has made a series of leadership appointments to support delivery of its ambitious growth strategy across key global markets, in response to rising demand for the company\u2019s OOC solutions by pharma and biotech companies. Rumbelow joins the team to drive the scale-up of its
\nR&D activities, where he will work closely with recently-appointed chief scientific officer, Dr Tomasz Kostrzewski, to expand the company\u2019s PhysioMimix OOC range of MPS and incorporate the latest technological advances in the field to further extend their applications within preclinical research.<\/p>\n<\/div><\/section>
\n